POLYETHYLENE GLYCOL 3350

Post-LOE

polyethylene glycol 3350

Teva

ANDAORALFOR SOLUTION

Approved

May 2006

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

POLYETHYLENE GLYCOL 3350 (polyethylene glycol 3350) by Teva is osmotic activity [moa]. First approved in 2006.

Drug data last refreshed 19h ago

Mechanism of Action

Osmotic Activity

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (4)

NCT03060512Phase 4Completed

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

Started Mar 2017

276 enrolled

Opioid Induced Constipation

NCT02292459Phase 3Withdrawn

Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)

Started Dec 2015

Constipation

NCT01707667Phase 4Completed

Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity

Started Feb 2013

13 enrolled

Chronic Constipation

NCT01212445Phase 2Completed

Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)

Started Oct 2010

154 enrolled

Constipation

Company

Worked on POLYETHYLENE GLYCOL 3350 at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.